Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (603259) [3] Core Views - The company reported a revenue of 45.456 billion yuan for 2025, representing a year-on-year growth of 15.84%, and a net profit attributable to shareholders of 19.151 billion yuan, which is a significant increase of 102.65% [1][2] - For 2026, the company provides guidance for revenue growth in the range of 18% to 22%, expecting total revenue to reach between 51.3 billion and 53 billion yuan [2] - The company’s continuous business revenue for 2025 was 43.42 billion yuan, showing a year-on-year increase of 21.4%, surpassing the previous guidance of 17% to 18% [2] Financial Summary - The adjusted net profit for 2025 was 14.96 billion yuan, reflecting a year-on-year growth of 41.3% [2] - As of December 2025, the company had a backlog of orders amounting to 58 billion yuan, which is a 28.8% increase year-on-year, laying a solid foundation for future growth [2] - The TIDES business segment achieved revenue of 11.37 billion yuan in 2025, marking a remarkable year-on-year growth of 96% [5] - The chemical drug D&M business generated revenue of 19.92 billion yuan in 2025, with a year-on-year increase of 11.4% [5] - The laboratory testing and analysis business reported revenues of 4.04 billion yuan, with a year-on-year growth of 4.2% [6] Earnings Forecast and Valuation - The revenue forecast for 2026 has been adjusted to 52.157 billion yuan, with EPS projected at 7.29 yuan [7] - The company’s PE ratio is expected to be 13 times for 2026, indicating a favorable valuation compared to historical performance [7]

Investment Rating - The report maintains a positive outlook on WuXi AppTec, indicating a strong growth trajectory and a valuation reset [4]. Core Insights - WuXi AppTec's Q4 2025 performance aligns with earnings forecasts, with total revenue growth projected at 13-17% and sustainable business revenue growth at 18-22% for 2026, despite geopolitical uncertainties [4]. - The company has shown robust order momentum, with new orders in Q4 2025 increasing by 29% year-over-year, and TIDES orders accelerating from 17% to 20% growth [4][5]. - The recent stock price pullback is viewed as an opportunity for investment, as the increasing share of CMO (Contract Manufacturing Organization) business reduces sensitivity to interest rate changes and biotech financing [5]. Summary by Sections Company Overview - WuXi AppTec operates globally across Asia, Europe, and North America, providing comprehensive R&D and manufacturing services to advance the pharmaceutical and healthcare industries [10]. - The company covers the entire R&D cycle through five core business segments: small molecule R&D and manufacturing, biologics R&D and manufacturing, cell and gene therapy R&D and manufacturing, medical device testing, and molecular diagnostics and genomics [10]. Revenue Breakdown - Revenue by product category: Chemical business (72.3%), Testing business (16.2%), Biological business (6.3%), High-end therapeutic CTDMO (3.2%) [11]. - Revenue by region: Middle East and Africa (8.7%), Asia (36.5%), Europe (27.3%), Americas (27.5%) [11]. Growth Drivers - The overall order growth rate of 29% in Q4 2025 surpasses the TIDES order growth rate of 20%, suggesting a more balanced growth driver for 2026-27 [7]. - The number of CMO projects is expected to increase from 72 in Q4 2024 to 83 in Q4 2025, maintaining global competitiveness despite local supply chain trends [6]. Catalysts - Recent stock price fluctuations have enhanced valuation attractiveness, creating favorable investment opportunities [8].

Group 1 - Goldman Sachs reports that Kanglong Chemical has reached a cooperation agreement with Eli Lilly to support the local supply of Orforglipron in China [1] - Eli Lilly is expected to invest $200 million in Kanglong Chemical to enhance its technical capabilities, with potential for further expansion of the partnership as the project progresses [1] - The impact on Kanglong Chemical's fundamentals, including profit contribution and strategic significance, will depend on further disclosures expected during the upcoming earnings call [1] Group 2 - The report anticipates that Kanglong Chemical will receive a positive market response due to the partnership highlighting Eli Lilly's recognition of Kanglong Chemical as a qualified local GLP-1 supply chain partner [1] - Goldman Sachs assigns a "Buy" rating for Kanglong Chemical's Hong Kong stock with a target price of HKD 30.7, and a "Neutral" rating for its A-shares with a target price of CNY 38 [1]

Core Insights - WuXi AppTec (603259.SH, 02359) announced the latest progress of its GLP-1 drug pipeline at the 44th JPMorgan Healthcare Conference, revealing support for 24 GLP-1 drugs [1] - The company is developing 24 GLP-1 drugs, including both small molecules and peptides, with 15 already in Phase II and III clinical trials, positioning the company to capture approximately 25% of the global GLP-1 market [1] - The ongoing shortage of GLP-1 drugs highlights deficiencies in the core pharmaceutical supply chain, with demand experiencing unprecedented exponential growth [1] Industry Developments - Some pharmaceutical companies have successfully navigated shortages by efficiently outsourcing to selected external partners while mobilizing internal resources, demonstrating flexible and expanding production methods [1] - As a key player in the global core pharmaceutical supply chain, WuXi AppTec has proactively built its production capacity, recently completing the construction of a 100,000-liter solid-phase synthesis reactor to enhance large-scale production capabilities [1] - The increasing accessibility of GLP-1 drugs is expected to reshape the treatment landscape for obesity and related metabolic diseases, indicating the beginning of a "therapeutic revolution" [1]

Core Viewpoint - WuXi AppTec (02268) anticipates significant financial performance growth for the fiscal year ending December 31, 2025, with substantial increases in revenue, gross profit, and adjusted net profit, indicating strong operational momentum and effective cost control [1] Financial Performance Summary - Revenue is expected to grow by over 45% compared to the fiscal year ending December 31, 2024 [1] - Gross profit is projected to increase by over 70%, indicating improved profit margins and cost management [1] - Adjusted net profit before interest income and expenses is forecasted to rise by over 45%, with a growth rate exceeding 65% when excluding foreign exchange impacts, highlighting robust core business profitability [1] - Net profit is anticipated to grow by over 38%, despite adverse effects from foreign exchange and interest rate fluctuations [1]

Core Viewpoint - WuXi AppTec (02268.HK) anticipates significant financial growth for the fiscal year ending December 31, 2025, with revenue and profit metrics expected to exceed previous year's performance by substantial margins [1] Financial Performance Summary - Revenue is projected to grow by over 45% compared to the fiscal year ending December 31, 2024 [1] - Gross profit is expected to increase by more than 70% compared to the fiscal year ending December 31, 2024, indicating effective optimization of product/service profit margins and cost control [1] - Adjusted net profit before interest income and expenses is anticipated to rise by over 45% compared to the fiscal year ending December 31, 2024, with a growth rate exceeding 65% when excluding foreign exchange impacts, confirming strong profit growth momentum in core operations [1] - Net profit is forecasted to grow by over 38% compared to the fiscal year ending December 31, 2024, despite adverse effects from foreign exchange and interest rate fluctuations [1]

Core Viewpoint - Morgan Stanley maintains WuXi AppTec (603259) as a top pick for 2026, setting a target price of 130 RMB for its A-shares and rating it as "Overweight" [1] Financial Performance - WuXi AppTec's revenue for 2025 is projected to increase by 15.8% to 45.5 billion RMB, while profit is expected to rise by 102.7% to 19.2 billion RMB [1] - Adjusted profit under non-IFRS standards is anticipated to grow by 41.3% to 15 billion RMB [1] Business Segments - Revenue from continuing operations is expected to grow by 21.4%, surpassing management's forecast of 17% to 18%, driven by strong performance in the chemical business and TIDES [1] - The company confirmed two significant one-time gains during the year, including approximately 1.4 billion RMB from the sale of its testing business [1]

Core Viewpoint - The company, Haoyuan Pharmaceutical, is actively expanding its global presence and enhancing its operational efficiency, as evidenced by its recent performance and strategic initiatives [1] Group 1: Business Operations - The company has established 8 business centers, 6 research centers, and 4 production bases across various regions including China, the USA, Europe, India, Hong Kong, Japan, South Korea, and Southeast Asia [1] - The company utilizes a cross-regional collaboration mechanism between domestic professionals and international business personnel to quickly respond to the needs of over 10,000 global clients [1] Group 2: Partnerships and Collaborations - The company has formed partnerships with multiple multinational pharmaceutical giants, renowned global universities, research institutions, and CRO companies [1] - Stable collaborations have been established with numerous well-known overseas distributors specializing in drug research reagents [1] Group 3: Revenue Performance - In the first half of 2025, the company's overseas revenue reached 560 million yuan, representing a year-on-year growth of 39.8% [1] - Overseas revenue accounted for 43.0% of the main business income, an increase of nearly 5 percentage points compared to the previous year [1] - The company has achieved same-day order and next-day delivery in most regions of the USA and China, providing a convenient purchasing experience that outperforms imported brands [1]

Core Viewpoint - The company, Haoyuan Pharmaceutical, emphasizes its commitment to a development strategy focused on "industrialization, globalization, and branding," aiming for steady growth across its three main business engines [1] Group 1: Business Development - The revenue from the ADC (Antibody-Drug Conjugate) business currently constitutes a significant portion of the revenue from the backend innovative drug CDMO (Contract Development and Manufacturing Organization) [1] - The company has established a strong competitive advantage in the ADC small molecule sector, with the successful operation of its Chongqing ADC CDMO base in March marking the formation of a comprehensive service system across Shanghai, Ma'anshan, and Chongqing [1] - Haoyuan has developed into a rare one-stop ADCCDMO enterprise in China, offering a full-chain closed-loop service capability that includes Payload-Linker development, antibody discovery, conjugation process optimization, and commercial production [1] Group 2: Market Expansion and Strategy - The company is actively promoting market outreach and project advancement in Chongqing, with a rapid increase in new signed orders [1] - A strategic investment department has been established, and the company does not rule out the possibility of expanding its international market presence through mergers, acquisitions, and partnerships [1] - The company has no undisclosed information that needs to be revealed, and any significant investment or acquisition plans will be communicated through relevant announcements [1]

Core Viewpoint - Ruizhi Pharmaceutical (300149) announced the resignation of its board secretary, Xu Jian, due to work adjustments, effective immediately upon delivery of the resignation report [1] Group 1: Management Changes - Xu Jian will continue to serve as the Vice President of the Investment Development Department at Shanghai Ruizhi Pharmaceutical Research Group after resigning [1] - Gao Yingying has been appointed as the new board secretary, with her term lasting until the end of the sixth board session [1] Group 2: New Board Secretary Profile - Gao Yingying, born in 1994, is a Chinese national with no permanent residency abroad and is currently pursuing a Master's degree in Business Administration at Shanghai Normal University [1] - Her previous experience includes roles as a planner, host, director, and editor at various broadcasting stations from 2016 to 2022, and as a promotion director at Zhongshan Anxin New Retail Co., Ltd. from November 2022 to November 2025 [1]